课题基金 / 基金详情

Pathomics biomarkers for stratification of clear cell kidney cancers

Pathomics biomarkers for stratification of clear cell kidney cancers
用于透明细胞肾癌分层的病理组学生物标志物
批准号:
10578582
负责人:
BEATRICE S KNUDSEN
金额:
$21.57万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-02-06 至 2025-01-31
关键词:
Adipose tissueAdjuvantAdjuvant TherapyAlgorithmsArchitectureBiological MarkersBlood VesselsCancer PrognosisCellular MorphologyClassificationClear CellClear cell renal cell carcinomaClinicalClinical Practice GuidelineClinical TrialsCorrelation StudiesDataDetectionDiagnosisDisease ProgressionDisease-Free SurvivalFatty acid glycerol estersFundingFutureGrantGrowthGuidelinesHigh-Risk CancerHistologicHistologyImmunotherapyInvadedMachine LearningMalignant NeoplasmsManualsMapsMetastatic Neoplasm to Lymph NodesModelingMorphologyNational Comprehensive Cancer NetworkNecrosisNephrectomyNuclear GradeOperative Surgical ProceduresPathologicPathologistPathologyPatient SelectionPatient-Focused OutcomesPatientsPatternPerformancePharmacotherapyPhase III Clinical TrialsPractice GuidelinesProbabilityPrognosisPrognostic MarkerRecommendationRecurrenceRecurrent Malignant NeoplasmRecurrent diseaseRecurrent tumorRegional CancerRenal Cell CarcinomaRenal carcinomaRiskRisk AssessmentSelection CriteriaSlideSourceStagingStratificationSystemic TherapyTestingThe Cancer Genome AtlasThrombusTissue imagingTissuesTrainingTumor Cell InvasionTumor ExpansionTumor TissueTumor stageUniversitiesUtahVenousWorkanti-PD-L1 antibodiesbiomarker developmentcancer biomarkerscancer diagnosiscancer recurrencecancer surgerycancer typecohortcomputer generatedconvolutional neural networkdigitaldraining lymph nodeexperiencehigh riskimprovedinnovationkidney surgerylarge datasetsnovelpathology imagingperformance testspredictive markerpredictive modelingprognosticprognostic assaysprognosticationrandom forestrisk stratificationside effecttissue biomarkerstumortumor growthtumor progression

项目摘要

项目成果

BEATRICE S KNUDSEN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Pathologic attributes of cancers, such as histology and tumor growth patterns are not quantitatively assessed to date. In every cancer type these parameters effect patient outcomes and are included in risk models of tumor recurrence and overall survival. Algorithms using machine learning and convolutional neural networks allow us to quantify pathology and develop Pathomics biomarkers. Here, we propose to obtain pathomics biomarkers of cancer recurrence/progression that enumerate histology growth patterns (HGPs) in clear cell renal cell cancer (ccRCC). ccRCC is the most common subtype of kidney cancer. In its localized stage, it is treated by nephrectomy. However, about 30% of patients experience disease progression after surgery and may benefit from adjuvant treatment. Deciding whether or not treatment is warranted requires identifying patients who are at a high risk of recurrence. Here, we hypothesize that quantitative biomarkers will improve the risk assessment of patients with ccRCC and propose to develop computer-generated features of tumor growth patterns. We previously defined 13 HGPs and demonstrated their ability to predict overall survival in patients treated for ccRCC. Distinctive features for each HGP will be generated and validated using frameworks of convolutional neural networks that produce probabilities of expression across cancer regions. Further, the distribution of probabilities will be used to obtain biomarkers of expression of each HGP. Using parametric and non-parametric models, HGP-biomarkers will be examined for their association with tumor stage and local mechanisms of ccRCC progression, such as formation of tumor thrombi, regional lymph node metastases or invasion into perinephric adipose tissues. The performance of each algorithm in the project will be evaluated. Altogether, biomarkers developed in this project will provide a starting point to select patients with ccRCC for adjuvant treatment after surgery.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
In vivo effects of sulforaphane supplementation on normal human prostate
In vivo effects of sulforaphane supplementation on normal human prostate
Clinical Specimen Management and Characterization Core
In vivo effects of sulforaphane supplementation on normal human prostate
海外基金